دورية أكاديمية
أعرض في EDS

Exploring Cannabinoids with Enhanced Binding Affinity for Targeting the Expanded Endocannabinoid System: A Promising Therapeutic Strategy for Alzheimer's Disease Treatment.

التفاصيل البيبلوغرافية
العنوان: Exploring Cannabinoids with Enhanced Binding Affinity for Targeting the Expanded Endocannabinoid System: A Promising Therapeutic Strategy for Alzheimer's Disease Treatment.
المؤلفون: Stanciu GD; Advanced Research and Development Center for Experimental Medicine 'Prof. Ostin C. Mungiu'-CEMEX, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania., Ababei DC; Advanced Research and Development Center for Experimental Medicine 'Prof. Ostin C. Mungiu'-CEMEX, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania.; Pharmacodynamics and Clinical Pharmacy Department, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania., Solcan C; Faculty of Veterinary Medicine, 'Ion Ionescu de la Brad' University of Life Sciences, 700490 Iasi, Romania., Uritu CM; Advanced Research and Development Center for Experimental Medicine 'Prof. Ostin C. Mungiu'-CEMEX, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania., Craciun VC; Department of Computer Science, 'Alexandru Ioan Cuza' University of Iasi, 700506 Iasi, Romania., Pricope CV; Advanced Research and Development Center for Experimental Medicine 'Prof. Ostin C. Mungiu'-CEMEX, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania., Szilagyi A; Advanced Research and Development Center for Experimental Medicine 'Prof. Ostin C. Mungiu'-CEMEX, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania., Tamba BI; Advanced Research and Development Center for Experimental Medicine 'Prof. Ostin C. Mungiu'-CEMEX, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania.; Department of Pharmacology, Clinical Pharmacology and Algesiology, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania.
المصدر: Pharmaceuticals (Basel, Switzerland) [Pharmaceuticals (Basel)] 2024 Apr 19; Vol. 17 (4). Date of Electronic Publication: 2024 Apr 19.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101238453 Publication Model: Electronic Cited Medium: Print ISSN: 1424-8247 (Print) Linking ISSN: 14248247 NLM ISO Abbreviation: Pharmaceuticals (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, c2004-
مستخلص: Despite decades of rigorous research and numerous clinical trials, Alzheimer's disease (AD) stands as a notable healthcare challenge of this century, with effective therapeutic solutions remaining elusive. Recently, the endocannabinoid system (ECS) has emerged as an essential therapeutic target due to its regulatory role in different physiological processes, such as neuroprotection, modulation of inflammation, and synaptic plasticity. This aligns with previous research showing that cannabinoid receptor ligands have the potential to trigger the functional structure of neuronal and brain networks, potentially impacting memory processing. Therefore, our study aims to assess the effects of prolonged, intermittent exposure (over 90 days) to JWH-133 (0.2 mg/kg) and an EU-GMP certified Cannabis sativa L. (Cannabixir ® Medium Flos, 2.5 mg/kg) on recognition memory, as well as their influence on brain metabolism and modulation of the expanded endocannabinoid system in APP/PS1 mice. Chronic therapy with cannabinoid receptor ligands resulted in reduced anxiety-like behavior and partially reversed the cognitive deficits. Additionally, a reduction was observed in both the number and size of Aβ plaque deposits, along with decreased cerebral glucose metabolism, as well as a decline in the expression of mTOR and CB2 receptors. Furthermore, the study revealed enlarged astrocytes and enhanced expression of M1 mAChR in mice subjected to cannabinoid treatment. Our findings highlight the pivotal involvement of the extended endocannabinoid system in cognitive decline and pathological aspects associated with AD, presenting essential preclinical evidence to support the continued exploration and assessment of cannabinoid receptor ligands for AD treatment.
References: Acta Neuropathol Commun. 2018 Oct 16;6(1):104. (PMID: 30322407)
Life Sci. 2019 Jan 15;217:25-33. (PMID: 30500552)
Cell Death Differ. 2009 Mar;16(3):378-85. (PMID: 19057621)
Acta Neuropathol. 2017 Feb;133(2):155-175. (PMID: 28025715)
J Nucl Med. 2016 Jun;57(6):954-60. (PMID: 26912428)
J Alzheimers Dis. 2013;35(4):847-58. (PMID: 23515018)
Neurochem Int. 2022 May;155:105311. (PMID: 35218870)
Nat Aging. 2023 May;3(5):494-505. (PMID: 37202515)
Neuropsychopharmacology. 2020 Jul;45(8):1330-1338. (PMID: 32375160)
Neurobiol Aging. 2012 May;33(5):933-44. (PMID: 20961663)
Acta Neuropathol. 2010 Jan;119(1):7-35. (PMID: 20012068)
Methods Mol Biol. 2019;1897:289-298. (PMID: 30539453)
Front Biosci (Schol Ed). 2012 Jan 01;4(3):941-52. (PMID: 22202101)
J Alzheimers Dis. 2015;43(3):977-91. (PMID: 25125475)
Neurobiol Aging. 2012 Sep;33(9):1995-2005. (PMID: 22079157)
Pharmacol Res. 2021 Aug;170:105729. (PMID: 34119623)
Mol Neurodegener. 2024 Jan 16;19(1):5. (PMID: 38229094)
Pharmaceuticals (Basel). 2023 May 03;16(5):. (PMID: 37242477)
Neurochem Int. 2012 Oct;61(5):739-48. (PMID: 22797007)
Mol Med. 2014 Mar 14;20:29-36. (PMID: 24722782)
Glia. 2023 Jan;71(1):44-59. (PMID: 35822691)
Front Pharmacol. 2022 Dec 22;13:1094351. (PMID: 36618946)
Curr Neuropharmacol. 2018;16(5):508-518. (PMID: 28730967)
Neuropharmacology. 2001 Jul;41(1):118-29. (PMID: 11445192)
J Neuroinflammation. 2012 Jan 16;9:8. (PMID: 22248049)
CMAJ. 2023 Oct 30;195(42):E1446-E1448. (PMID: 37903526)
Neurosci Lett. 2006 Sep 1;404(3):342-6. (PMID: 16837132)
Cell Signal. 2020 Jun;70:109545. (PMID: 31978506)
Curr Neuropharmacol. 2023;21(3):715-726. (PMID: 35105293)
Molecules. 2022 Mar 10;27(6):. (PMID: 35335180)
Cell. 2013 Nov 21;155(5):1154-1165. (PMID: 24267894)
J Neurochem. 2018 Oct;147(1):71-83. (PMID: 29989183)
Curr Opin Psychiatry. 2013 Jul;26(4):325-9. (PMID: 23689549)
Pharmaceutics. 2021 Nov 01;13(11):. (PMID: 34834237)
Front Psychiatry. 2020 Jun 30;11:602. (PMID: 32695029)
Neurobiol Aging. 2012 May;33(5):867-77. (PMID: 20961662)
Immunity. 2017 Jun 20;46(6):957-967. (PMID: 28636962)
Int J Mol Sci. 2020 Dec 22;22(1):. (PMID: 33375006)
Biomed Pharmacother. 2021 Jul;139:111623. (PMID: 33915504)
Brain Res. 2020 Dec 15;1749:147135. (PMID: 32980333)
Neuropharmacology. 2015 Dec;99:242-55. (PMID: 25979486)
J Neuroinflammation. 2018 May 24;15(1):158. (PMID: 29793509)
Pharmacol Biochem Behav. 2017 Dec;163:9-19. (PMID: 29107728)
Neurobiol Aging. 2013 Jul;34(7):1790-8. (PMID: 23402900)
J Ethnopharmacol. 2018 May 10;217:98-106. (PMID: 29447949)
Biology (Basel). 2021 Jun 17;10(6):. (PMID: 34204237)
J Neurochem. 2008 Aug;106(4):1586-93. (PMID: 18513369)
Nat Neurosci. 2021 Mar;24(3):312-325. (PMID: 33589835)
Brain Res. 2009 Aug 4;1283:148-54. (PMID: 19505450)
Pharmaceuticals (Basel). 2023 Nov 16;16(11):. (PMID: 38004485)
Drug Dev Res. 2020 Apr;81(2):141-143. (PMID: 32125005)
Neuron. 2008 Mar 27;57(6):883-93. (PMID: 18367089)
Front Aging Neurosci. 2022 Apr 12;14:870517. (PMID: 35493943)
Cells. 2021 Aug 07;10(8):. (PMID: 34440788)
Neuropharmacology. 2021 Jun 1;190:108352. (PMID: 33035532)
Neurobiol Aging. 2013 Mar;34(3):791-804. (PMID: 22795792)
Glia. 2019 Dec;67(12):2221-2247. (PMID: 31429127)
Mol Med Rep. 2019 Aug;20(2):1479-1487. (PMID: 31257471)
J Med Case Rep. 2022 Jul 12;16(1):277. (PMID: 35820856)
Front Neurosci. 2021 Oct 28;15:747229. (PMID: 34776851)
Glia. 2021 Aug;69(8):1852-1881. (PMID: 33634529)
Curr Diab Rep. 2019 Nov 4;19(11):117. (PMID: 31686231)
Mol Neurodegener. 2019 Aug 2;14(1):32. (PMID: 31375134)
Biomol Ther (Seoul). 2018 May 1;26(3):274-281. (PMID: 29463072)
Front Pharmacol. 2023 Mar 03;14:1053680. (PMID: 36959856)
معلومات مُعتمدة: PN-III-P1-1.1-PD-2021-0466, within PNCDI III This work was supported by a grant from the Ministry of Research, Innovation and Digitaliza-tion, CNCS-UEFISCDI
فهرسة مساهمة: Keywords: APP/PS1 transgenic mice; Alzheimer’s disease; cannabinoid receptor ligands; chronic intermittent therapy; expanded endocannabinoid system; therapeutic tools
تواريخ الأحداث: Date Created: 20240427 Latest Revision: 20240429
رمز التحديث: 20240429
مُعرف محوري في PubMed: PMC11053678
DOI: 10.3390/ph17040530
PMID: 38675490
قاعدة البيانات: MEDLINE
الوصف
تدمد:1424-8247
DOI:10.3390/ph17040530